{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:53:14Z","timestamp":1790916794281,"version":"4.1.0"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":154,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101280","type":"journal-article","created":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T17:53:45Z","timestamp":1781459625000},"page":"101280","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Management of high-risk biochemical recurrence in prostate cancer: A GCC Delphi consensus (BEAM Panel)"],"prefix":"10.1016","volume":"48","author":[{"given":"Mofarej","family":"AlHogbani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8913-8158","authenticated-orcid":false,"given":"Shouki","family":"Bazarbashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Alsharm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny M.","family":"Rabah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emad","family":"Tashkandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"AlRabiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Aseafan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"AlHomsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Ashour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mubarak","family":"AlMansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naif","family":"AlDaham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2026.101280_bib0001","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin"},{"key":"10.1016\/j.ctarc.2026.101280_bib0002","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.eururo.2024.11.013","article-title":"Recent patterns and trends in global prostate cancer incidence and mortality: an update","volume":"87","author":"Schafer","year":"2025","journal-title":"Eur. Urol"},{"key":"10.1016\/j.ctarc.2026.101280_bib0003","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.eururo.2011.02.026","article-title":"Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence","volume":"59","author":"Boorjian","year":"2011","journal-title":"Eur. Urol"},{"key":"10.1016\/j.ctarc.2026.101280_bib0004","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0094-0143(05)70163-4","article-title":"Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience","volume":"28","author":"Han","year":"2001","journal-title":"Urol. Clin. North Am."},{"key":"10.1016\/j.ctarc.2026.101280_bib0005","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on prostate Cancer\u20142024 update. Part I: screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur. Urol"},{"key":"10.1016\/j.ctarc.2026.101280_bib0006","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1001\/jama.294.4.433","article-title":"Risk of prostate cancer\u2013Specific mortality following biochemical recurrence after radical prostatectomy","volume":"294","author":"Freedland","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.ctarc.2026.101280_bib0007","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.eururo.2014.09.029","article-title":"Understanding long-term urinary adverse events after treatment of localized prostate cancer: a key tool in informed decision-making","volume":"67","author":"Laviana","year":"2015","journal-title":"Eur. Urol"},{"key":"10.1016\/j.ctarc.2026.101280_bib0008","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S1470-2045(16)00107-8","article-title":"Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial","volume":"17","author":"Duchesne","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctarc.2026.101280_bib0009","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ctarc.2026.101280_bib0010","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1007\/s00259-022-06089-w","article-title":"PSMA PET\/CT: joint EANM procedure guideline\/SNMMI procedure standard for prostate cancer imaging 2.0","volume":"50","author":"Fendler","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.ctarc.2026.101280_bib0011","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","article-title":"Improved outcomes with enzalutamide in biochemically recurrent prostate cancer","volume":"389","author":"Freedland","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2026.101280_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2025.09.103","article-title":"LBA87 EMBARK: overall survival with enzalutamide in biochemically recurrent prostate cancer","volume":"36","author":"Shore","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2026.101280_bib0013","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.euo.2024.11.005","article-title":"Apalutamide in metastatic castration-sensitive prostate cancer: results from the Multicenter real-world ARON-3 study","volume":"8","author":"Santoni","year":"2025","journal-title":"Eur. Urol. Oncol"},{"key":"10.1016\/j.ctarc.2026.101280_bib0014","doi-asserted-by":"crossref","unstructured":"T. B\u00fcttner, M. Rizzo, L. Bernal Vaca, J. Molina-Cerrillo, T. Alonso-Gordoa, A. Ju\u00e1rez, T. Buchler, E. Seront, J. Kucharz, M.N. Gandur Quiroga, M.T. Bourlon, M. B\u00f6gemann, J. Kopecky, P. Rescigno, O. Fiala, A. Rodriguez-Vida, Z.W. Myint, Y. \u00dcr\u00fcn, S. Scagliarini, A. Poprach, D. Matthews, H. Li, A. Rizzo, A. Mosca, E. Lenci, B. Melichar, M. Wenzel, P. Mandell, F. Massari, E.S. Antonarakis, M. Santoni, Enzalutamide in metastatic hormone-sensitive prostate cancer: results from the international, multicentre, real-world ARON-3 study, Prostate Cancer Prostatic Dis. (2026). https:\/\/doi.org\/10.1038\/S41391-025-01067-3.","DOI":"10.1038\/s41391-025-01067-3"},{"key":"10.1016\/j.ctarc.2026.101280_bib0015","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14040907","article-title":"PARP inhibitors and radiometabolic approaches in metastatic castration-resistant prostate cancer: what\u2019s now, what\u2019s new, and what\u2019s coming?","volume":"14","author":"Marchetti","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ctarc.2026.101280_bib0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers13030546","article-title":"Bone targeting agents in patients with metastatic prostate cancer: state of the art","volume":"13","author":"Mollica","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ctarc.2026.101280_bib0017","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s11523-022-00925-7","article-title":"Addressing challenges and controversies in the management of prostate cancer with multidisciplinary teams","volume":"17","author":"Shore","year":"2022","journal-title":"Target. Oncol"},{"key":"10.1016\/j.ctarc.2026.101280_bib0018","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.juro.2006.10.097","volume":"177","author":"Cookson","year":"2007","journal-title":"J. Urol."},{"key":"10.1016\/j.ctarc.2026.101280_bib0019","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/JU.0000000000003892","article-title":"Salvage therapy for prostate cancer: AUA\/ASTRO\/SUO guideline part I: introduction and treatment decision-making at the time of suspected biochemical recurrence after radical prostatectomy","volume":"211","author":"Morgan","year":"2024","journal-title":"J. Urol."},{"key":"10.1016\/j.ctarc.2026.101280_bib0020","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO phoenix consensus Conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ctarc.2026.101280_bib0021","doi-asserted-by":"crossref","first-page":"140","DOI":"10.6004\/jnccn.2024.0019","article-title":"Prostate cancer, version 3.2024","volume":"22","author":"Schaeffer","year":"2024","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.ctarc.2026.101280_bib0022","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-046588","article-title":"A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design","volume":"11","author":"Freedland","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.ctarc.2026.101280_bib0023","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial","volume":"36","author":"Ost","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101280_bib0024","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s40644-024-00752-1","article-title":"Prognostic significance of a negative PSMA PET\/CT in biochemical recurrence of prostate cancer","volume":"24","author":"Harsini","year":"2024","journal-title":"Cancer Imaging"},{"key":"10.1016\/j.ctarc.2026.101280_bib0025","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.e17071","article-title":"Characteristics and treatment (Tx) patterns (TxP) of high-risk biochemically recurrent (HR-BCR) non-metastatic castration-sensitive prostate cancer in the real-world by race, age, and prostate-specific antigen (PSA) doubling time (PSADT)","volume":"42","author":"Morgans","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101280_bib0026","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.52971","article-title":"PSMA-PET\/CT findings in patients with high-risk biochemically recurrent prostate cancer with No metastatic disease by conventional imaging","volume":"8","author":"Holzgreve","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.ctarc.2026.101280_bib0027","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.crad.2007.05.022","article-title":"The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis","volume":"63","author":"H\u00f6vels","year":"2008","journal-title":"Clin. Radiol"},{"key":"10.1016\/j.ctarc.2026.101280_bib0028","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s00345-023-04724-1","article-title":"Size of lymph-node metastases in prostate cancer patients undergoing radical prostatectomy: implication for imaging and oncologic follow-up of 2705 lymph-node positive patients","volume":"42","author":"Falkenbach","year":"2024","journal-title":"World J. Urol"},{"key":"10.1016\/j.ctarc.2026.101280_bib0029","doi-asserted-by":"crossref","first-page":"552","DOI":"10.2967\/jnumed.119.240929","article-title":"Appropriate use criteria for imaging evaluation of biochemical recurrence of prostate cancer after definitive primary treatment","volume":"61","author":"Jadvar","year":"2020","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ctarc.2026.101280_bib0030","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1464-410X.2004.04927.x","article-title":"Radionuclide bone scintigraphy in patients with biochemical recurrence after radical prostatectomy: when is it indicated?","volume":"94","author":"Gomez","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.ctarc.2026.101280_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2016.05.026","article-title":"Localizing sites of disease in patients with rising serum prostate-specific antigen up to 1 ng\/ml following prostatectomy: how much information can conventional imaging provide?","volume":"34","author":"Vargas","year":"2016","journal-title":"Urol. Oncol.: Semin. Orig. Investig."},{"key":"10.1016\/j.ctarc.2026.101280_bib0032","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1038\/sj.bjc.6605334","article-title":"Imaging metastatic bone disease from carcinoma of the prostate","volume":"101","author":"Messiou","year":"2009","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ctarc.2026.101280_bib0033","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.acra.2023.08.044","article-title":"Detection rate of PSMA PET using different ligands in men with biochemical recurrent prostate cancer following radical treatment: a systematic review and meta-analysis of prospective studies","volume":"31","author":"Wu","year":"2024","journal-title":"Acad. Radiol"},{"key":"10.1016\/j.ctarc.2026.101280_bib0034","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.euo.2022.04.006","article-title":"Diagnostic performance of prostate-specific membrane antigen positron emission tomography\u2013targeted biopsy for detection of clinically significant prostate cancer: a systematic review and meta-analysis","volume":"5","author":"Kawada","year":"2022","journal-title":"Eur. Urol. Oncol"},{"key":"10.1016\/j.ctarc.2026.101280_bib0035","doi-asserted-by":"crossref","first-page":"786","DOI":"10.2967\/jnumed.118.219501","article-title":"Metaanalysis of 68 Ga-PSMA-11 PET accuracy for the detection of prostate cancer validated by histopathology","volume":"60","author":"Hope","year":"2019","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ctarc.2026.101280_bib0036","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/S1470-2045(19)30415-2","article-title":"18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial","volume":"20","author":"Calais","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctarc.2026.101280_bib0037","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2967\/jnumed.119.237602","article-title":"Impact of 68 Ga-PSMA-11 PET\/CT on staging and management of prostate cancer patients in various clinical settings: a prospective single-center study","volume":"61","author":"Sonni","year":"2020","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ctarc.2026.101280_bib0038","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.2967\/jnumed.117.192476","article-title":"Impact of 68 Ga-PSMA-11 PET on management in patients with biochemically recurrent prostate cancer","volume":"58","author":"Hope","year":"2017","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ctarc.2026.101280_bib0039","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.eururo.2025.05.006","article-title":"The role of prostate-specific membrane antigen positron emission tomography for assessment of local recurrence and distant metastases in patients with biochemical recurrence of prostate cancer after definitive treatment: a systematic review and Meta-anal\u2026","volume":"88","author":"Mazzone","year":"2025","journal-title":"Eur. Urol"},{"key":"10.1016\/j.ctarc.2026.101280_bib0040","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","article-title":"Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial","volume":"5","author":"Fendler","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctarc.2026.101280_bib0041","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1158\/1078-0432.CCR-20-4573","article-title":"Diagnostic performance of 18F-DCFPyL-PET\/CT in men with biochemically recurrent prostate cancer: results from the CONDOR phase 3, Multicenter study","volume":"27","author":"Morris","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101280_bib0042","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/JU.0000000000001369","article-title":"Detection rate of prostate specific membrane antigen tracers for positron emission tomography\/computerized tomography in prostate cancer biochemical recurrence: a systematic review and network meta-analysis","volume":"205","author":"Crocerossa","year":"2021","journal-title":"J. Urol."},{"key":"10.1016\/j.ctarc.2026.101280_bib0043","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","volume":"77","author":"Perera","year":"2020","journal-title":"Eur. Urol"},{"key":"10.1016\/j.ctarc.2026.101280_bib0044","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2967\/jnumed.117.198119","article-title":"Prostate cancer molecular Imaging standardized evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET\/CT","volume":"59","author":"Eiber","year":"2018","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ctarc.2026.101280_bib0045","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2967\/jnumed.117.195255","article-title":"Proposal for a structured reporting system for prostate-specific membrane antigen\u2013Targeted PET imaging: PSMA-RADS Version 1.0","volume":"59","author":"Rowe","year":"2018","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ctarc.2026.101280_bib0046","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.2967\/jnumed.117.204677","article-title":"68 Ga-PSMA-HBED-CC uptake in cervical, celiac, and sacral ganglia as an important pitfall in prostate cancer PET imaging","volume":"59","author":"Rischpler","year":"2018","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ctarc.2026.101280_bib0047","doi-asserted-by":"crossref","DOI":"10.1002\/bco2.70028","article-title":"PSMA PET\/CT findings in high-risk biochemical recurrence after local treatment of prostate cancer","volume":"6","author":"Handa","year":"2025","journal-title":"BJUI Compass"},{"key":"10.1016\/j.ctarc.2026.101280_bib0048","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctarc.2026.101280_bib0049","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial","volume":"36","author":"Ost","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101280_bib0050","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.eururo.2023.10.012","article-title":"The efficacy and safety of metastasis-directed therapy in patients with prostate cancer: a systematic review and meta-analysis of prospective studies","volume":"85","author":"Miszczyk","year":"2024","journal-title":"Eur. Urol"},{"key":"10.1016\/j.ctarc.2026.101280_bib0051","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.ijrobp.2022.09.006","article-title":"Addition of metastasis-directed therapy to intermittent hormone therapy for oligometastatic prostate cancer (EXTEND): a multicenter, randomized phase II trial","volume":"114","author":"Tang","year":"2022","journal-title":"Int. J. Radiat. Oncol.*Biol.*Phys."},{"key":"10.1016\/j.ctarc.2026.101280_bib0052","unstructured":"EAU Guidelines on Prostate Cancer. Treatment chapter., European Association of Urology (n.d.). https:\/\/uroweb.org\/guidelines\/prostate%E2%80%90cancer\/chapter\/treatment (accessed May 31, 2026)."},{"key":"10.1016\/j.ctarc.2026.101280_bib0053","first-page":"14","article-title":"Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions","volume":"11","author":"Paller","year":"2013","journal-title":"Clin. Adv. Hematol. Oncol"},{"key":"10.1016\/j.ctarc.2026.101280_bib0054","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1200\/JCO.23.01157","article-title":"PRESTO: a phase III, open-label study of intensification of androgen blockade in patients with high-risk biochemically relapsed castration-sensitive prostate cancer (AFT-19)","volume":"42","author":"Aggarwal","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101280_bib0055","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1201546","article-title":"Intermittent androgen suppression for rising PSA level after radiotherapy","volume":"367","author":"Crook","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2026.101280_bib0056","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2490-14-9","article-title":"Intermittent versus continuous androgen deprivation for locally advanced, recurrent or metastatic prostate cancer: a systematic review and meta-analysis","volume":"14","author":"Botrel","year":"2014","journal-title":"BMC Urol"},{"key":"10.1016\/j.ctarc.2026.101280_bib0057","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.eururo.2012.07.040","article-title":"Advanced prostate cancer treated with intermittent or continuous androgen deprivation in the randomised FinnProstate study VII: quality of life and adverse effects","volume":"63","author":"Salonen","year":"2013","journal-title":"Eur. Urol"},{"key":"10.1016\/j.ctarc.2026.101280_bib0058","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1111\/j.1464-410X.2012.11120.x","article-title":"Intermittent hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial","volume":"110","author":"Mottet","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.ctarc.2026.101280_bib0059","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ajur.2017.04.001","article-title":"Intermittent androgen deprivation therapy in patients with prostate cancer: connecting the dots","volume":"4","author":"Abrahamsson","year":"2017","journal-title":"Asian J. Urol"},{"key":"10.1016\/j.ctarc.2026.101280_bib0060","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.eururo.2012.07.040","article-title":"Advanced prostate cancer treated with intermittent or continuous androgen deprivation in the randomised FinnProstate study VII: quality of life and adverse effects","volume":"63","author":"Salonen","year":"2013","journal-title":"Eur. Urol"},{"key":"10.1016\/j.ctarc.2026.101280_bib0061","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.eururo.2013.03.055","article-title":"Locally advanced and metastatic prostate cancer treated with intermittent androgen monotherapy or maximal androgen blockade: results from a randomised phase 3 study by the south european Uroncological group","volume":"66","author":"da Silva","year":"2014","journal-title":"Eur. Urol"},{"key":"10.1016\/j.ctarc.2026.101280_bib0062","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.eururo.2020.11.010","article-title":"A systematic review and meta-analysis of local salvage therapies after radiotherapy for prostate cancer (MASTER)","volume":"80","author":"Valle","year":"2021","journal-title":"Eur. Urol"},{"key":"10.1016\/j.ctarc.2026.101280_bib0063","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3390\/cancers13020244","article-title":"Functional outcomes after local salvage therapies for radiation-recurrent prostate cancer patients: a systematic review","volume":"13","author":"Abufaraj","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ctarc.2026.101280_bib0064","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103429","article-title":"Impact of treatment suspension on health-related quality of life in the EMBARK trial: a post hoc analysis","volume":"87","author":"Freedland","year":"2025","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.ctarc.2026.101280_bib0065","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1186\/s12872-024-04421-w","article-title":"Androgen deprivation therapy use and the risk of heart failure in patients with prostate cancer: a systematic review and meta-analysis","volume":"24","author":"Khorram","year":"2024","journal-title":"BMC Cardiovasc. Disord"},{"key":"10.1016\/j.ctarc.2026.101280_bib0066","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1157857","article-title":"Adverse cardiovascular effect following gonadotropin-releasing hormone antagonist versus GnRH agonist for prostate cancer treatment: a systematic review and meta-analysis","volume":"14","author":"Gu","year":"2023","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.ctarc.2026.101280_bib0067","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2004325","article-title":"Oral Relugolix for androgen-deprivation therapy in advanced prostate cancer","volume":"382","author":"Shore","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2026.101280_bib0068","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1001\/jamaoncol.2024.1549","article-title":"Cardiovascular events and androgen receptor signaling inhibitors in advanced prostate cancer","volume":"10","author":"El-Taji","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctarc.2026.101280_bib0069","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00774-024-01497-4","article-title":"Androgen deprivation therapy-related fracture risk in prostate cancer: an insurance claims database study in Japan","volume":"42","author":"Matsushima","year":"2024","journal-title":"J. Bone Min. Metab"},{"key":"10.1016\/j.ctarc.2026.101280_bib0070","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","volume":"361","author":"Smith","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2026.101280_bib0071","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1210\/jc.2011-3045","article-title":"Osteoporosis in men: an Endocrine Society clinical practice guideline","volume":"97","author":"Watts","year":"2012","journal-title":"J. Clin. Endocrinol. Metab"},{"key":"10.1016\/j.ctarc.2026.101280_bib0072","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1093\/annonc\/mdx521","article-title":"ESMO International consortium study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in countries outside of Europe","volume":"28","author":"Cherny","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2026.101280_bib0073","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.annonc.2024.12.005","article-title":"ESMO global consortium study on the availability, out-of-pocket costs, and accessibility of cancer medicines: 2023 update","volume":"36","author":"Cherny","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2026.101280_bib0074","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100335","article-title":"Please mind the gap\u2014about equity and access to care in oncology","volume":"6","author":"Barcellini","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctarc.2026.101280_bib0075","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ctrv.2015.11.007","article-title":"The impact of multidisciplinary team meetings on patient assessment, management and outcomes in oncology settings: a systematic review of the literature","volume":"42","author":"Pillay","year":"2016","journal-title":"Cancer Treat. Rev"},{"key":"10.1016\/j.ctarc.2026.101280_bib0076","doi-asserted-by":"crossref","first-page":"4159","DOI":"10.3390\/cancers13164159","article-title":"The effects of multidisciplinary team meetings on clinical practice for colorectal, lung, prostate and breast cancer: a systematic review","volume":"13","author":"Ko\u010do","year":"2021","journal-title":"Cancers"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226001917?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226001917?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:55:57Z","timestamp":1790913357000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226001917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":76,"alternative-id":["S2468294226001917"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101280","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of high-risk biochemical recurrence in prostate cancer: A GCC Delphi consensus (BEAM Panel)","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101280","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101280"}}